Deloitte January 9, 2024

Explore our 2024 life sciences M&A predictions

Life sciences M&A was a bright spot across the wider dealmaking world in 2023. Will this positive trend continue over the next 12 months? We think so. We’re making five bold 2024 life sciences M&A predictions, which include another strong year for pharma M&A and a positive turn for the MedTech market. Find out what...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
New insights into how cells generate microRNAs
Navigating CMC insights for success in drug development
Novartis pays $1bn upfront for Huntington's drug from PTC
The Real Reasons Drug Prices Are So High
FDA Approves Sixth Ustekinumab Biosimilar, Yesintek

Share This Article